Us Congress 2025-2026 Regular Session

Us Congress Senate Bill SB297 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	II
2	2	119THCONGRESS
3	3	1
4	4	STSESSION S. 297
5	5	To amend title XXVII of the Public Health Service Act to require group
6	6	health plans and health insurance issuers offering group or individual
7	7	health insurance coverage to provide coverage for prostate cancer
8	8	screenings without the imposition of cost-sharing requirements, and for
9	9	other purposes.
10	10	IN THE SENATE OF THE UNITED STATES
11	11	JANUARY29, 2025
12	12	Mr. B
13	13	OOZMAN(for himself and Mr. BOOKER) introduced the following bill;
14	14	which was read twice and referred to the Committee on Health, Edu-
15	15	cation, Labor, and Pensions
16	16	A BILL
17	17	To amend title XXVII of the Public Health Service Act
18	18	to require group health plans and health insurance
19	19	issuers offering group or individual health insurance cov-
20	20	erage to provide coverage for prostate cancer screenings
21	21	without the imposition of cost-sharing requirements, and
22	22	for other purposes.
23	23	Be it enacted by the Senate and House of Representa-1
24	24	tives of the United States of America in Congress assembled, 2
25	25	VerDate Sep 11 2014 21:15 Feb 25, 2025 Jkt 059200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\S297.IS S297
26	26	kjohnson on DSK7ZCZBW3PROD with $$_JOB 2
27	27	•S 297 IS
28	28	SECTION 1. SHORT TITLE. 1
29	29	This Act may be cited as the ‘‘Prostate-Specific Anti-2
30	30	gen Screening for High-risk Insured Men Act’’ or the 3
31	31	‘‘PSA Screening for HIM Act’’. 4
32	32	SEC. 2. FINDINGS. 5
33	33	Congress finds the following: 6
34	34	(1) Prostate cancer is the second leading cause 7
35	35	of cancer death in men in the United States with 1 8
36	36	in 44 men dying from prostate cancer and more 9
37	37	than 35,700 men estimated to die from prostate 10
38	38	cancer in 2025. 11
39	39	(2) Prostate cancer is the second most com-12
40	40	monly diagnosed cancer in the Nation with 1 in 8 13
41	41	men being diagnosed in their lifetimes, 3,300,000 14
42	42	men in the United States living with a diagnosis, 15
43	43	and over 310,000 men estimated to be diagnosed in 16
44	44	2025. 17
45	45	(3) The survival rate for prostate cancer diag-18
46	46	nosed in early stage is near 100 percent but prostate 19
47	47	cancer diagnosed in late stage has only a 37-percent 20
48	48	survival rate. 21
49	49	(4) There are few, if any, symptoms of prostate 22
50	50	cancer before it reaches late stage. 23
51	51	(5) African-American men have a disproportion-24
52	52	ately higher rate of prostate cancer and are 70 per-25
53	53	cent more likely to be diagnosed with prostate can-26
54	54	VerDate Sep 11 2014 21:15 Feb 25, 2025 Jkt 059200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\S297.IS S297
55	55	kjohnson on DSK7ZCZBW3PROD with $$_JOB 3
56	56	•S 297 IS
57	57	cer than White men, with 1 in 6 African-American 1
58	58	men developing prostate cancer in their lifetimes. 2
59	59	(6) African-American men are 2.1 times more 3
60	60	likely to die from prostate cancer than White men. 4
61	61	(7) Men with a father or brother with prostate 5
62	62	cancer are more than twice as likely to be diagnosed 6
63	63	with prostate cancer than men without a family his-7
64	64	tory. 8
65	65	(8) The common clinical definition for men at 9
66	66	high-risk of prostate cancer includes African-Amer-10
67	67	ican men and men with a family history. 11
68	68	(9) Most of the major cancer and urological so-12
69	69	cieties recommend beginning screening discussions 13
70	70	earlier for African-American men and those with a 14
71	71	family history of prostate cancer. 15
72	72	(10) The United States Preventive Services 16
73	73	Task Force has encouraged research on screening 17
74	74	African-American men, including whether to screen 18
75	75	African-American men at younger ages, and has 19
76	76	identified this research as a high-priority cancer re-20
77	77	search gap. 21
78	78	(11) Barriers to screening should be minimized 22
79	79	for high-risk men in order to catch asymptomatic 23
80	80	prostate cancer before it metastasizes and the sur-24
81	81	vival rate is dramatically reduced. 25
82	82	VerDate Sep 11 2014 21:15 Feb 25, 2025 Jkt 059200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6201 E:\BILLS\S297.IS S297
83	83	kjohnson on DSK7ZCZBW3PROD with $$_JOB 4
84	84	•S 297 IS
85	85	(12) The cost of treating metastatic prostate 1
86	86	cancer in the United States health care system is 2
87	87	hundreds of millions of dollars more annually than 3
88	88	the cost of treating localized, early-stage cancer. 4
89	89	SEC. 3. REQUIREMENT FOR GROUP HEALTH PLANS AND 5
90	90	HEALTH INSURANCE ISSUERS OFFERING 6
91	91	GROUP OR INDIVIDUAL HEALTH INSURANCE 7
92	92	COVERAGE TO PROVIDE COVERAGE FOR 8
93	93	PROSTATE CANCER SCREENINGS WITHOUT 9
94	94	IMPOSITION OF COST-SHARING REQUIRE-10
95	95	MENTS. 11
96	96	(a) I
97	97	NGENERAL.—Section 2713(a) of the Public 12
98	98	Health Service Act (42 U.S.C. 300gg–13(a)) is amend-13
99	99	ed— 14
100	100	(1) by striking paragraph (5); 15
101	101	(2) by redesignating paragraphs (1) through 16
102	102	(4) as subparagraphs (A) through (D), respectively, 17
103	103	and adjusting the margins accordingly; 18
104	104	(3) by striking ‘‘(a) I
105	105	NGENERAL—A group 19
106	106	health’’ and inserting the following: 20
107	107	‘‘(a) C
108	108	OVERAGE OF PREVENTIVEHEALTHSERV-21
109	109	ICES.— 22
110	110	‘‘(1) I
111	111	N GENERAL.—A group health’’; 23
112	112	(4) in paragraph (1), as so designated— 24
113	113	VerDate Sep 11 2014 21:15 Feb 25, 2025 Jkt 059200 PO 00000 Frm 00004 Fmt 6652 Sfmt 6201 E:\BILLS\S297.IS S297
114	114	kjohnson on DSK7ZCZBW3PROD with $$_JOB 5
115	115	•S 297 IS
116	116	(A) in subparagraph (B), as so redesig-1
117	117	nated, by striking ‘‘; and’’ and inserting a semi-2
118	118	colon; 3
119	119	(B) in subparagraph (C), as so redesig-4
120	120	nated, by striking the period and inserting a 5
121	121	semicolon; 6
122	122	(C) in subparagraph (D), as so redesig-7
123	123	nated— 8
124	124	(i) by striking ‘‘paragraph (1)’’ and 9
125	125	inserting ‘‘subparagraph (A)’’; and 10
126	126	(ii) by striking the period and insert-11
127	127	ing ‘‘; and’’; 12
128	128	(D) by inserting after subparagraph (D), 13
129	129	as so redesignated, the following: 14
130	130	‘‘(E) with respect to men who are age 40 15
131	131	and over and are at high risk of developing 16
132	132	prostate cancer (including African-American 17
133	133	men and men with a family history of prostate 18
134	134	cancer (as defined in paragraph (2))), such ad-19
135	135	ditional evidence-based preventive care and 20
136	136	screenings not described in subparagraph (A) 21
137	137	for prostate cancer.’’; and 22
138	138	(5) by striking the flush text at the end and in-23
139	139	serting the following: 24
140	140	VerDate Sep 11 2014 21:15 Feb 25, 2025 Jkt 059200 PO 00000 Frm 00005 Fmt 6652 Sfmt 6201 E:\BILLS\S297.IS S297
141	141	kjohnson on DSK7ZCZBW3PROD with $$_JOB 6
142	142	•S 297 IS
143	143	‘‘(2) MEN WITH A FAMILY HISTORY OF PROS -1
144	144	TATE CANCER DEFINED .—For purposes of para-2
145	145	graph (1)(E), the term ‘men with a family history 3
146	146	of prostate cancer’ means men who have a first-de-4
147	147	gree relative— 5
148	148	‘‘(A) who was diagnosed with prostate can-6
149	149	cer; 7
150	150	‘‘(B) who developed prostate cancer; 8
151	151	‘‘(C) whose death was a result of prostate 9
152	152	cancer; 10
153	153	‘‘(D) who have been diagnosed with a can-11
154	154	cer known to be associated with increased risk 12
155	155	of prostate cancer; or 13
156	156	‘‘(E) who has a genetic alteration known to 14
157	157	be associated with increased risk of prostate 15
158	158	cancer. 16
159	159	‘‘(3) C
160	160	LARIFICATION REGARDING BREAST CAN -17
161	161	CER SCREENING, MAMMOGRAPHY, AND PREVENTION 18
162	162	RECOMMENDATIONS .—For the purposes of this Act, 19
163	163	and for the purposes of any other provision of law, 20
164	164	the current recommendations of the United States 21
165	165	Preventive Service Task Force regarding breast can-22
166	166	cer screening, mammography, and prevention shall 23
167	167	be considered the most current other than those 24
168	168	issued in or around November 2009. 25
169	169	VerDate Sep 11 2014 21:15 Feb 25, 2025 Jkt 059200 PO 00000 Frm 00006 Fmt 6652 Sfmt 6201 E:\BILLS\S297.IS S297
170	170	kjohnson on DSK7ZCZBW3PROD with $$_JOB 7
171	171	•S 297 IS
172	172	‘‘(4) RULE OF CONSTRUCTION .—Nothing in 1
173	173	this subsection shall be construed to prohibit a plan 2
174	174	or issuer from providing coverage for services in ad-3
175	175	dition to those recommended by the United States 4
176	176	Preventive Services Task Force or to deny coverage 5
177	177	for services that are not recommended by such Task 6
178	178	Force.’’. 7
179	179	(b) E
180	180	FFECTIVEDATE.—The amendments made by 8
181	181	subsection (a) shall apply with respect to plan years begin-9
182	182	ning on or after January 1, 2025. 10
183	183	Æ
184	184	VerDate Sep 11 2014 21:15 Feb 25, 2025 Jkt 059200 PO 00000 Frm 00007 Fmt 6652 Sfmt 6301 E:\BILLS\S297.IS S297
185	185	kjohnson on DSK7ZCZBW3PROD with $$_JOB